|
1
|
Malaty HM and Nyren O: Epidemiology of
Helicobacter pylori infection. Helicobacter. 8 (Suppl
1):8–12. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chey WD and Wong BC: Practice Parameters
Committee of the American College of Gastroenterology. American
College of Gastroenterology guideline on the management of
Helicobacter pylori infection. Am J Gastroenterol.
102:1808–1825. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shin JM and Sachs G: Pharmacology of
proton pump inhibitors. Curr Gastroenterol Rep. 10:528–534.
2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lee SJ: Clinical Application of CYP2C19
Pharmacogenetics Toward More Personalized Medicine. Front Genet.
3(318)2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ishizaki T and Horai Y: Review article:
Cytochrome P450 and the metabolism of proton pump
inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 13
(Suppl 3):27–36. 1999.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zalloum I, Hakooz N and Arafat T: Genetic
polymorphism of CYP2C19 in a Jordanian population: Influence of
allele frequencies of CYP2C19*1 and CYP2C19*2
on the pharmacokinetic profile of lansoprazole. Mol Biol Rep.
39:4195–4200. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li-Wan-Po A, Girard T, Farndon P, Cooley C
and Lithgow J: Pharmacogenetics of CYP2C19: Functional and clinical
implications of a new variant CYP2C19*17. Br J Clin
Pharmacol. 69:222–230. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sim SC, Risinger C, Dahl ML, Aklillu E,
Christensen M, Bertilsson L and Ingelman-Sundberg M: A common novel
CYP2C19 gene variant causes ultrarapid drug metabolism relevant for
the drug response to proton pump inhibitors and antidepressants.
Clin Pharmacol Ther. 79:103–113. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Charan J and Biswas T: How to calculate
sample size for different study designs in medical research? Indian
J Psychol Med. 35:121–126. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sugimoto K, Uno T, Yamazaki H and Tateishi
T: Limited frequency of the CYP2C19*17 allele and its
minor role in a Japanese population. Br J Clin Pharmacol.
65:437–439. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dowdle WR: The principles of disease
elimination and eradication. Bull World Health Organ. 76 (Suppl
2):22–25. 1998.PubMed/NCBI
|
|
12
|
Yang JC, Lu CW and Lin CJ: Treatment of
Helicobacter pylori infection: Current status and future
concepts. World J Gastroenterol. 20:5283–5293. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mégraud F and Lamouliatte H: Review
article: The treatment of refractory Helicobacter pylori
infection. Aliment Pharmacol Ther. 17:1333–1343. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jarrar Y and Lee SJ: The functionality of
UDP-Glucuronosyltransferase genetic variants and their association
with drug responses and human diseases. J Pers Med.
11(11)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu
HM, Hsu WH, Yu FJ, Wu DC and Kuo FC: CYP2C19 polymorphism
influences Helicobacter pylori eradication. World J
Gastroenterol. 20:16029–16036. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu
Z, Huang Z and Zhang G: Effect of CYP2C19 genetic polymorphisms on
the efficacy of proton pump inhibitor-based triple therapy for
Helicobacter pylori eradication: A meta-analysis.
Helicobacter. 13:532–541. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shirasaka Y, Chaudhry AS, McDonald M,
Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N,
Unadkat JD, et al: Interindividual variability of CYP2C19-catalyzed
drug metabolism due to differences in gene diplotypes and
cytochrome P450 oxidoreductase content. Pharmacogenomics J.
16:375–387. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Miki I, Aoyama N, Sakai T, Shirasaka D,
Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, et
al: Impact of clarithromycin resistance and CYP2C19 genetic
polymorphism on treatment efficacy of Helicobacter pylori
infection with lansoprazole- or rabeprazole-based triple therapy in
Japan. Eur J Gastroenterol Hepatol. 15:27–33. 2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Take S, Mizuno M, Ishiki K, Nagahara Y,
Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, et al:
Interleukin-1beta genetic polymorphism influences the effect of
cytochrome P 2019 genotype on the cure rate of 1-week triple
therapy for Helicobacter pylori infection. Am J
Gastroenterol. 98:2403–2408. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kawabata H, Habu Y, Tomioka H, Kutsumi H,
Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M,
et al: Effect of different proton pump inhibitors, differences in
CYP2C19 genotype and antibiotic resistance on the eradication rate
of Helicobacter pylori infection by a 1-week regimen of
proton pump inhibitor, amoxicillin and clarithromycin. Aliment
Pharmacol Ther. 17:259–264. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Okudaira K, Furuta T, Shirai N, Sugimoto M
and Miura S: Concomitant dosing of famotidine with a triple therapy
increases the cure rates of Helicobacter pylori infections
in patients with the homozygous extensive metabolizer genotype of
CYP2C19. Aliment Pharmacol Ther. 21:491–497. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kurzawski M, Gawrońska-Szklarz B,
Wrześniewska J, Siuda A, Starzyńska T and Droździk M: Effect of
CYP2C19*17 gene variant on Helicobacter pylori
eradication in peptic ulcer patients. Eur J Clin Pharmacol.
62:877–880. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gawrońska-Szklarz B, Siuda A, Kurzawski M,
Bielicki D, Marlicz W and Droździk M: Effects of CYP2C19, MDR1, and
interleukin 1-B gene variants on the eradication rate of
Helicobacter pylori infection by triple therapy with
pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol.
66:681–687. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Park HG, Jung MK, Jung JT, Kwon JG, Kim
EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, et al: Randomised
clinical trial: A comparative study of 10-day sequential therapy
with 7-day standard triple therapy for Helicobacter pylori
infection in naïve patients. Aliment Pharmacol Ther. 35:56–65.
2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Choi HS, Chun HJ, Park SH, Keum B, Seo YS,
Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, et al: Comparison of
sequential and 7-, 10-, 14-d triple therapy for Helicobacter
pylori infection. World J Gastroenterol. 18:2377–2382.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liou JM, Chen CC, Chen MJ, Chen CC, Chang
CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, et al: Taiwan
Helicobacter Consortium: Sequential versus triple therapy for the
first-line treatment of Helicobacter pylori: A multicentre,
open-label, randomised trial. Lancet. 381:205–213. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gaikovitch EA, Cascorbi I, Mrozikiewicz
PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN and
Roots I: Polymorphisms of drug-metabolizing enzymes CYP2C9,
CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian
population. Eur J Clin Pharmacol. 59:303–312. 2003.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Scordo MG, Aklillu E, Yasar U, Dahl ML,
Spina E and Ingelman-Sundberg M: Genetic polymorphism of cytochrome
P450 2C9 in a Caucasian and a black African population. Br J Clin
Pharmacol. 52:447–450. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rudberg I, Mohebi B, Hermann M, Refsum H
and Molden E: Impact of the ultrarapid CYP2C19*17 allele
on serum concentration of escitalopram in psychiatric patients.
Clin Pharmacol Ther. 83:322–327. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hamdy SI, Hiratsuka M, Narahara K,
El-Enany M, Moursi N, Ahmed MS and Mizugaki M: Allele and genotype
frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19,
CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian
population. Br J Clin Pharmacol. 53:596–603. 2002.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Pedersen RS, Brasch-Andersen C, Sim SC,
Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H,
Kristensen VN, Brøsen K, et al: Linkage disequilibrium between the
CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles:
Identification of CYP2C haplotypes in healthy Nordic populations.
Eur J Clin Pharmacol. 66:1199–1205. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bravo-Villalta HV, Yamamoto K, Nakamura K,
Bayá A, Okada Y and Horiuchi R: Genetic polymorphism of CYP2C9 and
CYP2C19 in a Bolivian population: An investigative and comparative
study. Eur J Clin Pharmacol. 61:179–184. 2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen L, Qin S, Xie J, Tang J, Yang L, Shen
W, Zhao X, Du J, He G, Feng G, et al: Genetic polymorphism analysis
of CYP2C19 in Chinese Han populations from different geographic
areas of mainland China. Pharmacogenomics. 9:691–702.
2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee SJ, Kim WY, Kim H, Shon JH, Lee SS and
Shin JG: Identification of new CYP2C19 variants exhibiting
decreased enzyme activity in the metabolism of S-mephenytoin and
omeprazole. Drug Metab Dispos. 37:2262–2269. 2009.PubMed/NCBI View Article : Google Scholar
|
